Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Australian Household Spending Dips in December as RBA Tightens Policy 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Lotte Group is set to acquire a bioindustry CMO plant located in the United States. The move has been announced on Thursday, May 5, and this also signals the company’s entrance into the bio business.
Currently, the acquisition process for the contract manufacturing organization (CMO) facility is still ongoing. Investment banking industry insiders said that Lotte Group has taken this step to buy the CMO plant after it stated that the bioindustry will be its new growth engine.
According to The Korea Times, CMOs are firms that specialize in the production of biopharmaceuticals that were developed by other companies. Lotte Group’s new CMO business will be headed by Lee Won Jik, a former executive at Samsung Biologics that the company recently hired. He has been tasked to develop and grow this business unit that the Lotte Group set up.
Lee will also be leading the acquisition efforts of the CMO as per the report. It was only last month when the South Korean multinational conglomerate declared during its general shareholders' meeting that its next growth engine for the future will be the bioindustry. Lotte Holdings will be investing directly in this business and will provide support to help it grow and succeed.
Meanwhile, as part of its entrance into the CMO business, Lotte Group applied for a trademark for its new biz. The company registered “Lotte Biologics” with the Korean Intellectual Property Office (KIPO) to officially launch its bio venture.
It was added that under the new Lotte Biologics banner, Lotte will also be participating in the largest bioindustry expo in the world called the Bio International Convention (Bio USA) which is set to take place next month in San Diego, California.
KIPO revealed that Lotte Holdings applied for the patent last week and aside from the name, it also trademarked some business areas such as customized manufacturing of biopharmaceuticals and drug processing and medical diagnostic devices for virus testing, The Korea Herald reported.
“Registering the trademark of Lotte Biologics was a part of preparations for the group’s bio business,” an official of Lotte Holdings stated. “We are reviewing various ways to enter the bio industry, but nothing has been confirmed at the moment.”
